Recent News

• 04.01.2025 - ARS - Annual Report to Security Holders
• 04.01.2025 - DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.01.2025 - DEF 14A - Definitive proxy statements
• 03.28.2025 - Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity
• 03.21.2025 - 8-K - Current report
• 03.18.2025 - 3 - Initial statement of beneficial ownership of securities
• 03.18.2025 - 8-K - Current report
• 03.11.2025 - 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.11.2025 - 8-K - Current report
• 03.11.2025 - Corbus Pharmaceuticals Reports Q4 and 2024 Financial Results and Provides a Corporate Update

Recent Filings

• 03.21.2025 - 8-K Current report
• 03.18.2025 - 8-K Current report
• 03.18.2025 - 3 Initial statement of beneficial ownership of securities
• 03.11.2025 - 8-K Current report
• 03.11.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.11.2025 - EX-99.1 EX-99.1
• 03.07.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.06.2025 - 144 Report of proposed sale of securities